Sino Biopharmaceutical Limited Stock Return On Asset
| SBMFF Stock | USD 0.42 0.00 0.00% |
Sino Biopharmaceutical Limited fundamentals help investors to digest information that contributes to Sino Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Sino Pink Sheet. The fundamental analysis module provides a way to measure Sino Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sino Biopharmaceutica pink sheet.
Sino |
Sino Biopharmaceutical Limited Company Return On Asset Analysis
Sino Biopharmaceutica's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Sino Biopharmaceutica Return On Asset | 0.0451 |
Most of Sino Biopharmaceutica's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sino Biopharmaceutical Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Sino Biopharmaceutical Limited has a Return On Asset of 0.0451. This is 100.52% lower than that of the Healthcare sector and 100.19% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 132.21% lower than that of the firm.
Sino Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sino Biopharmaceutica's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sino Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sino Biopharmaceutica by comparing valuation metrics of similar companies.Sino Biopharmaceutica is currently under evaluation in return on asset category among its peers.
Sino Fundamentals
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 18.81 B | |||
| Shares Owned By Insiders | 47.86 % | |||
| Shares Owned By Institutions | 14.86 % | |||
| Price To Earning | 24.17 X | |||
| Price To Book | 2.51 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 26.86 B | |||
| Gross Profit | 21.53 B | |||
| EBITDA | 19.87 B | |||
| Net Income | 14.61 B | |||
| Cash And Equivalents | 15.67 B | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 5.21 B | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 1.55 X | |||
| Book Value Per Share | 1.64 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 0.06 X | |||
| Price To Earnings To Growth | 0.53 X | |||
| Number Of Employees | 25.55 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 10.91 B | |||
| Total Asset | 60.54 B | |||
| Working Capital | 6 B | |||
| Current Asset | 13.73 B | |||
| Current Liabilities | 7.73 B | |||
| Z Score | 1.2 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 0.74 % | |||
| Net Asset | 60.54 B | |||
| Last Dividend Paid | 0.083 |
About Sino Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sino Biopharmaceutical Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sino Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sino Biopharmaceutical Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.